Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9277MR)

This product GTTS-WQ9277MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9277MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6007MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ3714MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ9674MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ2462MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ1253MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ2204MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ12251MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ15205MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW